CEO Trey Martin placed on paid leave after court-ordered noncompete TRO; Carl Hull named interim CEO

MARAVAI LIFESCIENCES HOLDINGS, INC.

Delaware Court of Chancery issued TRO preventing Martin from working for Maravai; pending preliminary injunction hearing later this year.
Danaher subsidiaries filed suit alleging Martin breached noncompete agreement from prior employment.
Carl Hull, former CEO and current Executive Chairman, appointed interim CEO to manage day-to-day operations.
Martin remains on paid leave with same compensation package pending resolution.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William "Trey" Martin, III

Chief Executive Officer

MRVI · MARAVAI LIFESCIENCES HOLDINGS, INC.

Effective: 2022-10-18
Successor: Carl Hull
Filed: October 19, 2022, 7:59 PM ET

On October 18, 2022, Maravai LifeSciences Holdings, Inc. (the “Company”) placed William “Trey” Martin, III, Chief Executive Officer, on a paid leave of absence following the issuance of a temporary restraining order by the Delaware Court of Chancery preventing him from working for the Company pending further order of the Court in a lawsuit filed against him by his previous employer alleging violation of a noncompetition agreement.

Appointed (interim)

Carl Hull

Chief Executive Officer

MRVI · MARAVAI LIFESCIENCES HOLDINGS, INC.

Effective: 2022-10-18
Filed: October 19, 2022, 7:59 PM ET

the Board of Directors (the “Board”) of the Company has appointed Carl Hull, Executive Chairman of the Board, to serve as interim Chief Executive Officer to maintain continuity of the day-to-day operations and draw upon his extensive knowledge of the management of the Company due to his prior service as the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William "Trey" Martin, III departed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

Action: placed on paid leave
Role: Chief Executive Officer

Exact text from the filing

On October 18, 2022, Maravai LifeSciences Holdings, Inc. (the “Company”) placed William “Trey” Martin, III, Chief Executive Officer, on a paid leave of absence following the issuance of a temporary restraining order by the Delaware Court of Chancery preventing him from working for the Company pending further order of the Court in a lawsuit filed against him by his previous employer alleging violation of a noncompetition agreement.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl Hull was appointed as Chief Executive Officer at MARAVAI LIFESCIENCES HOLDINGS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board of Directors (the “Board”) of the Company has appointed Carl Hull, Executive Chairman of the Board, to serve as interim Chief Executive Officer to maintain continuity of the day-to-day operations and draw upon his extensive knowledge of the management of the Company due to his prior service as the Company’s Chief Executive Officer.

View on SEC.gov

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-22-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.